Discovery Life Sciences (Discovery), Biospecimen and Biomarker Specialists, today announced that it has officially qualified as one of Akoya Biosciences’ Global Service Providers . The qualification process assessed Discovery’s competency in staining, imaging and analysis, enabling the company to provide comprehensive spatial imaging services to researchers in discovery, translational and clinical research.
With this qualification, Discovery gains access to Akoya’s PhenoImager® HT workflows, which can provide information about the tumor microenvironment (TME), including the detail and spatially textured cellular co-expression between cell types There are unprecedented levels of These new spatial imaging technologies allow Discovery to better serve its immuno-oncology customers by dissecting the delicate and complex biological interactions between different cell types.
As a qualified vendor, Discovery has been provided with future panels and additional equipment for quantitative quality control of the operator and auto-stainer fixture. The company’s pathologist-driven, CAP-accredited, CLIA-certified, and GCLP-compliant multiplex immunofluorescence (MIF) assay development program draws heavily on decades of experience in histopathology, as well as expertise in microscopy powered by artificial intelligence and machine learning . Akoya’s spatial imaging technologies enhance Discovery’s capabilities, offering the highest quality multiplex IF stain with superior images and are fully customizable according to customer needs.
“Qualifying as Akoya Global Service Provider is an important milestone for Discovery,” said Christiaan Nielmann, Head of Global Tissue Biomarker Services at Discovery. “We are excited to leverage this technology to provide better insight into the tumor microenvironment for our biopharmaceutical customers. With Akoya’s reliable multiplex technology, we are able to perform rapid, high-quality analyzes on a single tissue slide.” helping us to better understand the mechanisms of complex diseases so that our customers can develop more effective treatments.”
About Discovery Life Sciences
Discovery Life Sciences is a specialist biospecimens and biomarkers company that combines the world’s largest commercial biospecimen inventory and acquisition network with leading multiomics biomarker service laboratories, including genomic, tissue biomarker, proteomic and protein-based services. Medicine and complementary clinical programs for cancer, infectious diseases and other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we commit to supply fresh and cryopreserved human cell material of clinical grade and research use only (RUO) to support programs of cell and gene therapy at any scale maintain the largest pool of recoverable donors for development and at any scale.
Driven by cutting-edge scientific expertise and innovative use of today’s technologies, Discovery’s team engages with customers to quickly remove barriers to critical research and development decision-making and deliver results at market-leading speeds. We are science at your service!